Who has been buying Pharmicell stock?

1 distinct insiders have filed 2 disclosed insider purchases in Pharmicell (005690), most recently on 2026-06-16. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Pharmicell have?

Pharmicell has 2 buy-side and 0 sell-side disclosures on record, covering ₩308M ($214K) in total reported value, spanning 2024-07-24 to 2026-06-16.

Where does StockDrifts get Pharmicell insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Pharmicell 005690

Company

파미셀Pharmicell

Insiders

Buys

Total Value

₩308M ($214K)

Avg Return

+55.62%

Last Filing

2026-06-16

Pharmicell (005690) has 2 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩308M ($214K) in reported transaction value. The earliest filing StockDrifts holds for Pharmicell is dated 2024-07-24; the most recent is 2026-06-16. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +55.62%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-16	BUY	PROGRAM	임영자 Youngja Lim	moving	668	-	-	-
2026-06-16	BUY	PROGRAM	배의한 double	moving	668	-	-	-
2026-06-16	BUY	PROGRAM	장학순 Jang Hak-soon	Managing Director	668	-	-	-
2026-06-16	BUY	PROGRAM	성현술 Seonghyeonsul	moving	668	-	-	-
2026-06-16	BUY	PROGRAM	김수찬 Kim Soo-chan	Senior Vice President	668	-	-	-
2026-06-16	BUY	PROGRAM	정순웅 Sunwoong Jeong	Managing Director	668	-	-	-
2026-01-28	BUY	Market Buy	김현수 Hyunsoo Kim	CEO	14.0K	₩14,220	+32.6%	₩199M ($138K)
2026-01-13	BUY	신규선임	성현술 Seonghyeonsul	moving	978	₩13,700	+37.6%	₩13M ($9K)
2025-04-30	BUY	Market Buy	김현수 Hyunsoo Kim	CEO	10.3K	₩10,550	+78.7%	₩109M ($75K)
2025-03-06	BUY	PROGRAM	김수찬 Kim Soo-chan	Managing Director	2.4K	₩10,200	+84.8%	₩24M ($17K)
2025-03-06	BUY	PROGRAM	정순웅 Sunwoong Jeong	Managing Director	2.4K	₩10,200	+84.8%	₩24M ($17K)
2025-03-06	BUY	PROGRAM	임영자 Youngja Lim	Head of Finance Division	635	₩10,200	+84.8%	₩6M ($4K)
2025-03-06	BUY	PROGRAM	배의한 double	Head of Finance Division	978	₩10,200	+84.8%	₩10M ($7K)
2025-03-06	BUY	PROGRAM	정길수 Gilsu Jeong	Managing Director	2.4K	₩10,200	+84.8%	₩24M ($17K)
2025-03-06	BUY	PROGRAM	장학순 Jang Hak-soon	Managing Director	2.4K	₩10,200	+84.8%	₩24M ($17K)
2024-07-24	BUY	기타	정길수 Gilsu Jeong	Managing Director	343	₩5,230	+260.4%	₩2M ($1K)
2024-07-24	BUY	기타	임영자 Youngja Lim	Head of Finance Division	343	₩5,230	+260.4%	₩2M ($1K)
2024-07-24	BUY	기타	김수찬 Kim Soo-chan	Managing Director	1.4K	₩5,230	+260.4%	₩7M ($5K)
2024-07-24	BUY	기타	정순웅 Sunwoong Jeong	Managing Director	1.4K	₩5,230	+260.4%	₩7M ($5K)
2024-07-24	BUY	기타	장학순 Jang Hak-soon	Managing Director	1.4K	₩5,230	+260.4%	₩7M ($5K)

Frequently asked questions

Who has been buying Pharmicell stock?: 1 distinct insiders have filed 2 disclosed insider purchases in Pharmicell (005690), most recently on 2026-06-16. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Pharmicell have?: Pharmicell has 2 buy-side and 0 sell-side disclosures on record, covering ₩308M ($214K) in total reported value, spanning 2024-07-24 to 2026-06-16.
Where does StockDrifts get Pharmicell insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Pharmicell. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.